Summary by Moomoo AI
On February 22, 2024, Moderna, Inc. reported its financial results for the fourth quarter and the full fiscal year of 2023. The company announced a fourth-quarter revenue of $2.8 billion, a decrease from the previous year's $5.1 billion, primarily due to reduced COVID-19 vaccine sales. Despite this, Moderna posted a GAAP net income of $217 million and a diluted EPS of $0.55 for the quarter. For the full year, revenues were $6.8 billion with a GAAP net loss of $(4.7) billion and a diluted EPS of $(12.33), largely impacted by non-cash charges and a tax valuation allowance. Moderna reaffirmed its 2024 product sales forecast of approximately $4 billion and expects regulatory approvals for its RSV vaccine for older adults in the first half of 2024. The company also anticipates key...Show More